Bulevirtide was recently conditionally approved by EMA and it is today the only specific treatment for hepatitis delta. However, questions remain about the length of treatment and the formulation requiring a daily subcutaneous injection, which could hamper its use in LMICs. Additionally, its safety and efficacy are still under evaluation and therefore bulevirtide has been included in the watchlist.